Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

29.49 -0.68 (-2.25%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday
Via Benzinga
What 4 Analyst Ratings Have To Say About Kymera Therapeutics
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
5 Analysts Have This to Say About Kymera Therapeutics
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Kymera Therapeutics Provides Webcast Information for December 14 Investor Event
Company to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
5 Analysts Have This to Say About Kymera Therapeutics
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Recap: Kymera Therapeutics Q3 Earnings
Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Kymera Therapeutics Announces Third Quarter 2022 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
5 Analysts Have This to Say About Kymera Therapeutics
  Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings: 
Via Benzinga
Kymera Therapeutics Appoints Biopharmaceutical Leader Victor Sandor, M.D.C.M., to Board of Directors
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Report Third Quarter 2022 Results on November 3
Company also presenting at upcoming investor conferences 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Kymera Therapeutics to Hold Investor Webcast on December 14 to Share Clinical Data from KT-474 Phase I Patient Cohort and Oncology Pipeline
From Kymera Therapeutics, Inc.
Via GlobeNewswire
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL). 
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed
Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26... 
Via Benzinga
Where Kymera Therapeutics Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
Kymera Therapeutics Stock Scores Rising Relative Price Strength
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022
  
Via Benzinga
Kymera Therapeutics: Q2 Earnings Insights
  Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022
  
Via Benzinga
Kymera Therapeutics Commences Initial-Stage Oncology Trials
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413. 
Via Benzinga
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022
Upgrades 
Via Benzinga
Why Kymera Therapeutics Stock Is Gaining Wednesday
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.